Discovery of the First C-Nucleoside HCV Polymerase Inhibitor (GS-6620) with Demonstrated Antiviral Response in HCV Infected Patients-Reference-Cited by-同舟云学术

Discovery of the First C-Nucleoside HCV Polymerase Inhibitor (GS-6620) with Demonstrated Antiviral Response in HCV Infected Patients

Published:2013-05-01 Issue:5 Volume:57 Page:1812-1825
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Cho Aesop¹,Zhang Lijun¹,Xu Jie¹,Lee Rick¹,Butler Thomas¹,Metobo Sammy¹,Aktoudianakis Vangelis¹,Lew Willard¹,Ye Hong¹,Clarke Michael¹,Doerffler Edward¹,Byun Daniel¹,Wang Ting¹,Babusis Darius¹,Carey Anne C.¹,German Polina¹,Sauer Dorothea¹,Zhong Weidong¹,Rossi Stephen¹,Fenaux Martijn¹,McHutchison John G.¹,Perry Jason¹,Feng Joy¹,Ray Adrian S.¹,Kim Choung U.¹

Affiliation:

1. Gilead Sciences, 333 Lakeside Drive, Foster City, California 94044, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm400201a

Reference28 articles.

1. Evolving epidemiology of hepatitis C virus

2. Expert opinion on the treatment of patients with chronic hepatitis C

3. The Era of Direct-Acting Antivirals Has Begun: The Beginning of the End for HCV?